After a bust with knee pain drug and 3 Covid-19 flops, Ampio lays off staff; Antibody startup nabs second deal in two weeks
Since at least April 2015, Ampio Pharmaceuticals has reeled from one Phase III fail after another for its knee osteoarthritis drug, known as Ampion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
